The 'Induction Drug' group was developed as a byproduct of the 'Suppressive Drug' group research. Developed by the Lorath Matriarchy, the 'Induction Drug' group has been developed from its byproduct stage to a fully developed product due to the drug's potentials in treatments and even recreational usage.
Based on Lorath nanomachine technology, the 'Induction' drug group induces organ functions, chemical production, neurotransmitter responses, neurotransmitter sensitivity, simulates preexisting functions. The 'Induction' drug group functions by utilizing nanomachines to actively seek out target organs, tissues, cells, nerves, and neurotransmitters and alter their function as prescribed by the nanomachine's programming. Such as in cases of alteration of neurotransmitter function, nanomachines would stimulate production of certain neurotransmitters, while also stimulating receptors to have an increased sensitivity to the produced neurotransmitter chemicals.
The psychological application of the 'Induction' drug group is actually much more straight forward than that of the 'Suppressive' drug group. 'Induction' drugs directly act upon glands, brain tissues, nerves, neurotransmitter production, and nerve receivers to induce the desired psychological result. Applied nanomachines are programmed with thresholds however to prevent excessive manipulation of the subject's internal chemistry to prevent harmful effects.
In physiological applications of the 'Induction' drug group, programmed nanomachines are used to seek out target tissues and alter function to suit the programmed intent. 'Induction' drugs when used to induce physiological results often target key glands, organs, and cell structures to induce desired results. 'Induction' drugs can be used to increase the production of bodily chemicals by the subject's organs, cells, and tissues, or to stimulate increased function of the subject's organs, cells, tissues, etc. An example of physiological 'Induction' drug usage would be the application of the drug to induce production of adrenaline by the subject's glands to increase blood flow during a failure of the subject's heart.
Many varieties of the 'Induction' drug group are available to the public without prescription and come pre-programmed for common tasks1). However, varieties which may pose a health risk must be prescribed by a health care professional.
It is advised that 'Induction' drugs intended for inducing autonomic behaviors and complex brain behaviors be used sparingly to prevent physiological damage or psychological unbalance. Users are not to continue use of these drugs for more than two weeks at a time. In the event of abnormal side effects such as stupor, depression, mania, digestive upset, respiratory upset, fainting, irrational behavior or thoughts, and unusual bleeding, the user is encouraged to consult a health care professional.